

## VPRIV® (velaglucerase alfa) Medication Precertification Request

Page 1 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Vpriv is non-preferred. The preferred products are Cerezyme and Elelyso.

Would you like to use electronic prior authorization? Consider using **Availity**, our electronic prior authorization portal. Learn more about **Availity** from the links in the table below.

For phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.

For Aetna Medicare Advantage and Allina Health Aetna Medicare members send request to:

Phone: <u>1-866-503-0857</u> (TTY: <u>711</u>)

Fax: 1-844-268-7263

Availity: https://www.aetna.com/health-care-professionals/resource-center/availity.html

For Aetna Medicare Advantage Virginia Dual Eligible Special Needs Plans (HMO D-SNP)

send request to:

Phone: <u>1-855-463-0933</u> Fax: <u>1-833-280-5224</u>

Availity: <a href="https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal">https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal</a>

For Aetna Assure Premier Plus Medicare Advantage New Jersey Dual Eligible Special Needs Plans

(HMO D-SNP) send request to:

Phone: <u>1-844-362-0934</u> Fax: <u>1-833-322-0034</u>

Availity: https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html

For Aetna Better Health of Illinois Premier Medicare Medicaid Plan (MMP) send request to:

Phone: <u>1-866-600-2139</u> FAX: <u>1-855-320-8445</u>

Availity: https://www.aetnabetterhealth.com/illinois/providers/portal

For Aetna Better Health of **Ohio Premier Medicare Medicaid Plan** (MMP) send request to:

Phone: <u>1-855-364-0974</u> Fax: <u>1-855-734-9389</u>

Availity: <a href="https://www.aetnabetterhealth.com/ohio/providers/portal">https://www.aetnabetterhealth.com/ohio/providers/portal</a>

For Aetna Better Health of Michigan Premier Medicare Medicaid Plan (MMP) send request to:

Phone: <u>1-855-676-5772</u> Fax: <u>1-844-241-2495</u>

Availity: https://www.aetnabetterhealth.com/michigan/providers/portal.html



## MEDICARE FORM VPRIV® (velaglucerase alfa) Medication Precertification Request

Page 2 of 3

(All fields must be completed and legible for Precertification Review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Vpriv is non-preferred. The preferred products are Cerezyme and Elelyso.

Please indicate: Start of treat Precertification Requested By:		<u>/</u>	ontinuation of therapy, da			1 1	
A. PATIENT INFORMATION							
First Name:		Last Name:					
Address:		1	City:		State:	ZIP:	
Home Phone:	Mork	Phone:	1	Phone:	Otato.	ZII .	
		riloile.	Cell	FIIOHE.	F		
	llergies:				Email:		
Current Weight: lbs	orkgs	Height:	inches or	cms			
B. INSURANCE INFORMATION							
Member ID #:		Does patient have other coverage? ☐ Yes ☐ No					
Group #:		es, provide ID#: Carrier Name:					
Insured:		Insured:					
Medicare: ☐ Yes ☐ No If yes,	provide ID #:	Medic	caid: ☐ Yes ☐ No If y	es, provide	ID #:		
C. PRESCRIBER INFORMATION							
First Name:		Last Name:	(Che	ck one):	M.D D	).O. □ N.P. □ P.A.	
Address:			City:	T	State:	ZIP:	
Phone: Fa	ax:	St Lic #:	NPI #:	DEA #:		UPIN:	
Provider Email:		Office Contact Name:			Phone:		
Specialty (Check one):   Hemat	ologist 🗌 Other:						
D. DISPENSING PROVIDER/ADI							
Outpatient Infusion Center Center Name:	Phone:	ZIP:	Dispensing Provider/II  Physician's Office  Specialty Pharmacy Name: Address: City: Phone: TIN: NPI:	Ref	tail Pharmacy ner: State: Fax:	ZIP:	
Request is for: VPRIV (velaglucerase alfa) Dose: Directions for Use:							
HCPCS Code:	,		•		·		
F. DIAGNOSIS INFORMATION -	Please indicate primary I	CD code and specify any ot	her any other where appl	cable (*).			
Primary ICD Code: Other ICD Code:							
G. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.							
☐ Cerezyme (ir  When was the n  Please describe  No Has the patient ha  ☐ Cerezyme (ir  When was the n	ad prior therapy with the ad a trial and failure of ar miglucerase)   Elelysonember's trial and failure the nature of the failure ad an adverse reaction to miglucerase)  Elelysonember's adverse reactice the nature of the adversentraindications or other mit all that apply)	requested product within the my of the following? (if yes, so (taliglucerase alfa) of the preferred drug? of the preferred drug on the preferred drug? (if yes (taliglucerase alfa) on to the preferred drug? e reaction to the preferred dedical reason(s) that the particular of the following is the preferred dedical reason(s) that the particular of the following is the preferred dedical reason(s) that the particular of the following is the following	elect all that apply below) s, select all that apply belo	ow)			



## MEDICARE FORM VPRIV® (velaglucerase alfa) Medication Precertification Request

Page 3 of 3

(All fields must be completed and legible for Precertification Review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Vpriv is non-preferred. The preferred products are Cerezyme and Elelyso.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.							
For All Requests (clinical documentation required for all requests):							
☐ Yes ☐ No Is this infusion request in an outpatient hospital setting?							
Yes No Has the patient experienced an adverse event with the requested product that has not responded to conventional							
interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or							
immediately after an infusion?							
Yes No Does the patient have severe venous access issues that require the use of special interventions only available in the							
outpatient hospital setting?							
Yes No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of							
the infusion therapy AND the patient does not have access to a caregiver?  Please provide a description of the behavioral issue or impairment:							
☐ Yes ☐ No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the							
member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be							
managed in an alternate setting without appropriate medical personnel and equipment?							
Please provide a description of the condition:   Cardiopulmonary:  ———————————————————————————————————							
Respiratory:							
☐ Renal:							
Please indicate which type of Gaucher disease the patient has been diagnosed with: Type 1 Type 2 Type 3 Other							
For Initiation Requests (clinical documentation required for all requests):							
Yes No Was the diagnosis of Gaucher disease confirmed by an enzyme assay demonstrating a deficiency of beta-glucocerebrosidase (glucosidase) enzyme activity or by genetic testing?							
☐ Yes ☐ No Has the patient had an ineffective response, contraindication, or intolerance to Elelyso?							
For Continuation Requests (clinical documentation required for all requests):							
Yes No Is the patient receiving benefit from therapy, defined as not experiencing an inadequate response or any intolerable adverse events from therapy?							
H. ACKNOWLEDGEMENT							
Request Completed By (Signature	Required):		Date://				
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive							
any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent							
insurance act, which is a crime and subjects such person to criminal and civil penalties.							

The plan may request additional information or clarification, if needed, to evaluate requests.